Table 2.
Survival in papillary tumors and predictors of poor prognosis
| Ref. | n/resected | Operative mortality (%) | Positive nodes (%) | R0 (%) | Pancreatobil/intestinal, n (%) |
Survival-resected |
Median survival - resected (mo) | Predictors of worse survival or recurrence | |
| 5 yr | 10 yr | ||||||||
| Albagli et al[128] | 50/50 | 8.0 | 36.0 | - | - | N0 52% | - | - | None |
| N+ 39% | |||||||||
| Allema et al[136] | 67/67 | 1.5 | 52.0 | 75.0 | - | 50% | - | R+ | |
| Beger et al[50] | 171/171 | 3.1 | 54.0 | 79.6 | - | N+ 21% | - | - | N+2, Pan+, R, Stage2, G2-3 |
| N0: 63% | |||||||||
| Bettschart et al[18] | 88/70 | 0.0 | 40.0 | 97.2 | 37.91 | 45.8 | Bilirubin2, Age > 70, G3, N+2, Neu+, Pan+ | ||
| Brown et al[91] | 72/51 | 2.0 | 47.0 | 100.0 | - | 58% | N+2, T, G | ||
| Carter et al[137] | 157/145 | - | 33.0 | 86.0 | 53 (45)-54 (46) | - | - | - | Pancreatobil2, Bilirubin, Stage2, N+, T, Ly+2, Neu+2 |
| Chareton et al[35] | 63/51 | 7.5 | - | - | - | 40% | - | Stage, Ampullectomy | |
| Choi et al[129] | 78/70 | 2.6 | 31.4 | 95.7 | - | 59.90% | 29% | 70 | Jaundice, Ulcerated, Pan+, G |
| N0 63.5% | |||||||||
| N+ 50.8% | |||||||||
| Di Giorgio1 et al[138] | 94/64 | 8.6 | 28.0 | 100.0 | - | 64.4% | 54 | No resection , Size, G, Depth of infiltration2 | |
| Duffy et al[92] | 55 | 0.0 | 41.8 | 98.2 | - | 67.70% | - | - | Neu+2 |
| Falconi et al[19] | 90/90 | 4.0 | 48.0 | 61% (disease free) | Stage, T, LNR2 | ||||
| Hornick et al[16] | 157/150 | 59.8 | Adenocarcinoma 45% | Jaundice, Stage, N+ | |||||
| 106 | Adenoma 82% | ||||||||
| Adenocarcinoma | N+ 47% | ||||||||
| N0 63% | |||||||||
| Howe1 et al[28] | 123/101 | 5.0 | 45.5 | 96.1 | - | 46% | - | 58.8 | No resection, N+2, R+2, G3 |
| Iacono et al[139] | 59/59 | 7.8 | 37.3 | - | - | 46% | 33% | 31 | G, T2, N+, Chromosome 17p2, 18q2, Micro satellite instab., Standard PD |
| Inoue et al[140] | 34/34 | 52.6% | N+2, Pan+, V+2, Neu+2, SMA2 | ||||||
| Kawaguchi et al[141] | 28/28 | 56.4% | 37 | Duo+, Ly+, V+2 | |||||
| Kim et al[34] | 104/104 | 39.4 | 62 (60)-42 (40) | 60.1% | 57.6% | T2, CEA, N+2, G32, Pancreatobil2, Neu+, Ly+ | |||
| Kimura et al[36] | 51 | - | 45.0 | - | 38 (74)-13 (25) | Pancreatobil | |||
| Klempnauer et al[142] | 94/94 | 9.6 | 38.0 | 97.0 | - | 34.5% | 28.6% | - | Size2, G3, N+, Stage |
| Lazaryan et al[20] | 72/72 | - | 34.0 | 96.0 | - | 61% | - | - | Neu+2, Ulcerated2, N+2, Stage, Weight loss |
| Norero et al[143] | 50/50 | 32% | 28 | N+2 | |||||
| Ohike et al[134] | 244/244 | - | 38.0 | 95.0 | 162 (66) other | 33% | - | - | Budding2, N+2, T2, R+2 |
| 82 (34) intestinal | Hi budding 24% | ||||||||
| Low budding 68% | |||||||||
| Qiao et al[59] | 127/127 | 9.7 | 35.0 | 98.4 | 43.3% | 35.7% | N+2, T2, Stage, Pan+ | ||
| Roder et al[144] | 69/66 | 4.5 | 42.0 | - | - | 35% | - | 41 | N(nr) |
| Sakata et al[130] | 71/71 | 0.0 | 48.0 | 97.2 | 64% | 55% | G, Pan+, Ly+2, V+2, Neu+, R+, N+2, LNR | ||
| Shinkawa et al[145] | 23/23 | 52% | 32% | Pan+, N+ | |||||
| Talamini1 et al[51] | 120/106 | 3.8 | 40.0 | - | - | 38% | - | 46 | No resection, Transfusion2, N+, G2-3 |
| N+ 31% | |||||||||
| N0 43% | |||||||||
| Todoroki et al[95] | 66/59 | 0.0 | 60.0 | 93.2 | - | 52.6% | R+, CEA, Ulcerated, T2, N+, Stage2, Ly+2, V+ | ||
| Westgaard et al[25] | 114/114 | 3.5 | 57.0 | 65.0 | 67 (59)-47 (41.2) | - | Pancreatobil2, N+2, V+2 | ||
| 41 ampullary | Size2 | ||||||||
| Winter et al[127] | 450/450 | 2.0 | 54.5 | 96.1 | Adenocarcinoma 45% | N+ 23.4 | N+2, Neu+2, Transfusion2 | ||
| Adenoca: 347 | Adenoma 86% | N0 79 | |||||||
| N+ 35% | |||||||||
| N0 56% | |||||||||
| Yokoyama et al[15] | 74/59 | - | 53.5 | 100.0 | - | 61.0% | 53% | - | Pan+2, N+2, Jaundice, V+, Ly+2, Neu+, G |
| Zhao et al[146] | 105/105 | 8.6 | 37.1 | 42.8% | Pan+, Size2, T, TNM stage, N(nr)2 | ||||
1
Including not resected pts;
2
Independent predictor; duo+: Duodenal invasion; G: Histologic grade of differentiation; LNR : Lymph nodes ratio; Ly+: Lymphatic vessel invasion; N+: pOsitive lymph nodes; N(nr): Number of metastatic lymph nodes; Neu+: Perineural invasion; Pan+: Pancreatic invasion; Pancreatobil: Pancreatobiliary histological subtype; R+: Positive resection margins; No resection: Patients not resected vs those who underwent surgical resection; SMA: Lymphadenectomy around the superior mesenteric artery; V+: Blood vessel invasion.